• Something wrong with this record ?

Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome

M. Maioli, S. Rinaldi, S. Cruciani, A. Necas, V. Fontani, G. Corda, S. Santaniello, A. Rinaldi, A. Pinheiro Barcessat, A. Necasova, A. Castagna, Z. Filipejova, C. Ventura, C. Fozza

. 2022 ; 71 (4) : 539-549. [pub] 20220728

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22022935

About 30 percent of patients diagnosed with myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML). The senescence of bone marrow?derived mesenchymal stem cells (BMSCs) seems to be one of the determining factors in inducing this drift. Research is continuously looking for new methodologies and technologies that can use bioelectric signals to act on senescence and cell differentiation towards the phenotype of interest. The Radio Electric Asymmetric Conveyer (REAC) technology, aimed at reorganizing the endogenous bioelectric activity, has already shown to be able to determine direct cell reprogramming effects and counteract the senescence mechanisms in stem cells. Aim of the present study was to prove if the anti-senescence results previously obtained in different kind of stem cells with the REAC Tissue optimization - regenerative (TO-RGN) treatment, could also be observed in BMSCs, evaluating cell viability, telomerase activity, p19ARF, P21, P53, and hTERT gene expression. The results show that the REAC TO-RGN treatment may be a useful tool to counteract the BMSCs senescence which can be the basis of AML drift. Nevertheless, further clinical studies on humans are needed to confirm this hypothesis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22022935
003      
CZ-PrNML
005      
20230518103739.0
007      
ta
008      
221007s2022 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934903 $2 doi
035    __
$a (PubMed)35899943
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Maioli, Margherita $u Department of Biomedical Sciences, University of Sassari, Sassari, Italy $u Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, Italy
245    10
$a Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome / $c M. Maioli, S. Rinaldi, S. Cruciani, A. Necas, V. Fontani, G. Corda, S. Santaniello, A. Rinaldi, A. Pinheiro Barcessat, A. Necasova, A. Castagna, Z. Filipejova, C. Ventura, C. Fozza
520    9_
$a About 30 percent of patients diagnosed with myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML). The senescence of bone marrow?derived mesenchymal stem cells (BMSCs) seems to be one of the determining factors in inducing this drift. Research is continuously looking for new methodologies and technologies that can use bioelectric signals to act on senescence and cell differentiation towards the phenotype of interest. The Radio Electric Asymmetric Conveyer (REAC) technology, aimed at reorganizing the endogenous bioelectric activity, has already shown to be able to determine direct cell reprogramming effects and counteract the senescence mechanisms in stem cells. Aim of the present study was to prove if the anti-senescence results previously obtained in different kind of stem cells with the REAC Tissue optimization - regenerative (TO-RGN) treatment, could also be observed in BMSCs, evaluating cell viability, telomerase activity, p19ARF, P21, P53, and hTERT gene expression. The results show that the REAC TO-RGN treatment may be a useful tool to counteract the BMSCs senescence which can be the basis of AML drift. Nevertheless, further clinical studies on humans are needed to confirm this hypothesis.
650    _2
$a buněčná diferenciace $7 D002454
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $7 D015470
650    12
$a myelodysplastické syndromy $x genetika $x metabolismus $x terapie $7 D009190
650    12
$a telomerasa $x metabolismus $7 D019098
650    _2
$a nádorový supresorový protein p53 $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rinaldi, Salvatore $u Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, Italy $u Research Department, Rinaldi Fontani Foundation, Florence, Italy
700    1_
$a Cruciani, Sara $u Department of Biomedical Sciences, University of Sassari, Sassari, Italy
700    1_
$a Nečas, Alois, $d 1966- $7 mzk2004229096 $u Faculty of Veterinary Medicine, University of Veterinary and Sciences Brno, Czech Republic
700    1_
$a Fontani, Vania $u Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, Italy $u Research Department, Rinaldi Fontani Foundation, Florence, Italy
700    1_
$a Corda, Giovanna $u Blood Diseases Department of Clinical and Experimental Medicine University of Sassari, Sassari, Italy
700    1_
$a Santaniello, Sara $u Department of Biomedical Sciences, University of Sassari, Sassari, Italy
700    1_
$a Rinaldi, Arianna $u Department of Biomedical Sciences, University of Sassari, Sassari, Italy $u Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, Italy $u Research Department, Rinaldi Fontani Foundation, Florence, Italy
700    1_
$a Pinheiro Barcessat, Ana Rita $u Department of Biomedical Sciences, University of Sassari, Sassari, Italy $u Health and Biological Sciences Department, Federal University of Amapá, Macapá, Brazil
700    1_
$a Nečasová, Andrea $7 xx0256997 $u Faculty of Veterinary Medicine, University of Veterinary and Sciences Brno, Czech Republic
700    1_
$a Castagna, Alessandro $u Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, Italy
700    1_
$a Filipejová, Zita $7 xx0301710 $u Faculty of Veterinary Medicine, University of Veterinary and Sciences Brno, Czech Republic
700    1_
$a Ventura, Carlo $u National Laboratory of Molecular Biology and Stem Cell Engineering – Eldor Lab, Istituto Nazionale di Biostrutture e Biosistemi (INNB), Innovation Accelerators, CNR, Bologna, Italy
700    1_
$a Fozza, Claudio $u Blood Diseases Department of Clinical and Experimental Medicine University of Sassari, Sassari, Italy
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 71, č. 4 (2022), s. 539-549
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35899943 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20221007 $b ABA008
991    __
$a 20230518103734 $b ABA008
999    __
$a ok $b bmc $g 1851692 $s 1174221
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 71 $c 4 $d 539-549 $e 20220728 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK198 $a Pubmed-20221007

Find record

Citation metrics

Archiving options